5 news items
Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
ONCT
30 May 24
by the study's Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
ONCT
30 May 24
was made by the study's Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
ONCT
18 Apr 24
), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
ONCT
18 Apr 24
inhibitor (DAARI), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study's Safety Review
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
ONCT
7 Mar 24
encouraging initial response results and we believe that the protocol amendments will further ensure patient safety as we investigate the optimal dose
- Prev
- 1
- Next